Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:689795.
doi: 10.1155/2014/689795. Epub 2014 Feb 17.

Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma

Giuseppe Lucarelli  1 , Pasquale Ditonno  1 , Carlo Bettocchi  1 , Antonio Vavallo  1 , Monica Rutigliano  1 , Vanessa Galleggiante  1 , Angela Maria Vittoria Larocca  2 , Giuseppe Castellano  3 , Loreto Gesualdo  3 , Giuseppe Grandaliano  4 , Francesco Paolo Selvaggi  1 , Michele Battaglia  1
Affiliations

Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma

Giuseppe Lucarelli et al. Dis Markers. 2014.

Abstract

CA 15-3, CA 125 and β-2 microglobulin are three common tumor markers currently used for diagnosis, prognosis, assessment of therapeutic response, and/or to evaluate recurrence in breast and ovarian cancer and malignant lymphoproliferative disorders, respectively. In the present prospective study we assessed the role of these three serum proteins as biomarkers for renal cell carcinoma (RCC), as well as any association between tumor marker levels and clinical-pathological parameters. CA 15-3, CA 125, and β-2 microglobulin were preoperatively measured in 332 patients who underwent nephrectomy for RCC. Estimates of cancer-specific survival (CSS) was calculated according to the Kaplan-Meier method. Multivariate analysis was performed to identify the most significant variables for predicting CSS. Preoperatively, 35.2% (n = 117), 9.6% (n = 32) and 30.4% (n = 101) of the patients had abnormal levels of CA 15-3, CA 125 and β-2 microglobulin, respectively. Statistically significant differences resulted between CA 15-3, CA 125 and β-2 microglobulin values and tumor size, Fuhrman grade, presence of lymph node, and visceral metastases. CSS was significantly decreased for patients with high levels of CA 15-3, CA 125, and β-2 microglobulin (P < 0.0001, P < 0.0001, and P = 0.001, resp.). At multivariate analysis only age, the presence of visceral metastases, and high levels of CA 15-3 were independent adverse prognostic factors for CSS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Differences in median CA 15-3 (a), CA 125 (b), and β-2 microglobulin (c) levels according to histological subtype and compared to healthy subjects (control).
Figure 2
Figure 2
Kaplan-Meier cancer-specific survival (CSS) curves, stratified by CA 15-3 (a), CA 125 (b), and β-2 microglobulin (c) serum levels.
Figure 3
Figure 3
Kaplan-Meier progression-free survival (PFS) curves, stratified by CA 15-3 (a), CA 125 (b), and β-2 microglobulin (c) serum levels.
Figure 4
Figure 4
Kaplan-Meier cancer-specific survival (CSS) curves for organ-confined (a) and advanced RCC (b), plotted against pre-operative CA 15-3 values.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer Journal for Clinicians. 2013;63(1):11–30. - PubMed
    1. Motzer RJ, Bander NH, Nanus DM. Medical progress: renal-cell carcinoma. The New England Journal of Medicine. 1996;335(12):865–875. - PubMed
    1. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. Journal of Urology. 2001;166(5):1611–1623. - PubMed
    1. Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78(5):1101–1106. - PubMed
    1. Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. Journal of Urology. 2008;179(6):2096–2102. - PubMed

MeSH terms